Interventional Cardiovascular Surgery

The study by Zahr et al. reports the results of an interim analysis assessing procedural and clinical outcomes at 30-day in 15 patients treated with the newly developed Medtronic Intrepid 35-F trans-femoral transcatheter mitral valve replacement (TMVR) system.

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Professor David J. Cohen presented the results of the economic outcomes of the PARTNER 3 trial on Friday, 5 November, in the Late-Breaking Trial session of the Transcatheter Cardiovascular Therapeutics Congress 2021. Giuseppe Biondi-Zoccai provides his analysis of this study.

Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.

In conducting the ACTIVATION trial, Redwood and colleagues seek to complement the existing literature with high-level evidence on whether percutaneous coronary intervention (PCI) prior to TAVR is non-inferior to conservative (no PCI) management.

Through this registry-based analysis, the authors sought to assess short and long-term outcomes of revascularisation in a latecomer STEMI population presenting between 12 to 48 hours of symptom onset.

Structural valve deterioration remains the Achilles heel of both SAVR and TAVI. Since indications for TAVI have expanded to low-risk patients in 2019, this clinical scenario poses a significant conundrum for physicians and surgeons, as the number of patients undergoing aortic valve interventions continues to grow...

Coronary obstruction is a known procedural complication of aortic valve replacement. However, delayed presentation few months after surgical AVR is a relatively unusual phenomenon.  We describe a 75 year old woman with surgical AVR who presented with acute coronary syndrome and severe RV failure few months...

Ali Nazmi Calik and Pascal Meier review this trial comparing CEA with CAS for patients with asymptomatic carotid stenosis, which was presented by Alison Halliday (Oxford, United Kingdom of Great Britain & Northern Ireland) during a Hot Line session of the ESC Congress 2021.